{"nctId":"NCT01682083","briefTitle":"Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD).","startDateStruct":{"date":"2013-01-08","type":"ACTUAL"},"conditions":["Melanoma"],"count":870,"armGroups":[{"label":"Dabrafenib and trametinib","type":"EXPERIMENTAL","interventionNames":["Drug: Dabrafenib","Drug: Trametinib"]},{"label":"Dabrafenib and trametinib placebos","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebos"]}],"interventions":[{"name":"Dabrafenib","otherNames":["GSK2118436"]},{"name":"Trametinib","otherNames":["GSK1120212"]},{"name":"Placebos","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Completely resected histologically confirmed high-risk \\[Stage IIIa (LN metastasis more than 1 mm), IIIb or IIIc cutaneous melanoma determined to be V600E/K mutation positive by a central laboratory. Patients presenting with initial resectable lymph node recurrence after a diagnosis of Stage I or II melanoma are eligible.\n* Surgically rendered free of disease no more than 12 weeks before randomization.\n* Recovered from definitive surgery (e.g. no uncontrolled wound infections or indwelling drains).\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Adequate hematologic, hepatic, renal and cardiac function.\n\nKey Exclusion Criteria:\n\n* Known mucosal or ocular melanoma or the presence of unresectable in-transit metastases.\n* Evidence of distant metastatic disease.\n* Prior systemic anti-cancer treatment and radiotherapy for melanoma; prior surgery for melanoma is allowed.\n* History of another malignancy or concurrent malignancy including prior malignant melanoma. Exceptions to this include: Patients who have been disease-free for 5 years or patients with a history completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible, for example cervical cancer in situ, atypical melanocytic hyperplasia or melanoma in situ, multiple primary melanomas, or other malignancies for which the patient has been disease free for \\> 5 years.\n* History or current evidence of cardiovascular risk.\n* History or current evidence of retinal vein occlusion (RVO) or central serous retinopathy (CSR)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Relapse-free Survival (RFS)","description":"Recurrence-free survival was defined as the time from randomization to disease recurrence (local recurrence, distant recurrence, second primary melanoma), or death from any cause.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43","spread":null},{"groupId":"OG001","value":"35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Overall Survival","description":"Overall survival (OS) of dabrafenib and trametinib as a combination therapy versus placebo","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"60","spread":null},{"groupId":"OG001","value":"93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"62","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"331","spread":null},{"groupId":"OG001","value":"277","spread":null}]}]}]},{"type":"SECONDARY","title":"Distant Metastasis-free Survival","description":"Distant metastasis-free survival (DMFS) of dabrafenib and trametinib as a combination therapy versus placebo. In the DMFS analysis, the first occurrence of distant metastasis or death (if it occurred before documented recurrence) was counted as an event.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"106","spread":null},{"groupId":"OG001","value":"150","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99","spread":null},{"groupId":"OG001","value":"131","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]},{"type":"SECONDARY","title":"Freedom From Relapse","description":"Freedom from relapse (FFR) of dabrafenib and trametinib as a combination therapy versus placebo. In the FFR analysis, local or distant recurrence or a new primary melanoma were counted as events, and patients who died of causes other than melanoma or treatment-related toxicity were censored.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"163","spread":null},{"groupId":"OG001","value":"247","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44","spread":null},{"groupId":"OG001","value":"36","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"229","spread":null},{"groupId":"OG001","value":"149","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":155,"n":435},"commonTop":["Fatigue","Pyrexia","Headache","Nausea","Diarrhoea"]}}}